Georgios Mylonas1,2, Franz Prager1,2, Barbara Wetzel1,2, Panagiotis Malamos3, Gabor Deak4, Michael Amon1,2. 1. 1 Department of Ophthalmology, Academic Teaching Hospital of St. John of God, Vienna - Austria. 2. 2 Sigmund Freud University, Medical School, Vienna - Austria. 3. 3 1st Department of Ophthalmology, "G. Gennimatas" General Hospital of Athens, University of Athens, Psychiko, Athens - Greece. 4. 4 Department of Ophthalmology, Medical University of Vienna, Vienna - Austria.
Abstract
PURPOSE: To describe a case of unilateral acute idiopathic maculopathy (UAIM) response to intravitreal therapy with aflibercept (Eylea). METHODS: Retrospective case report. RESULTS: A 36-year-old woman with sudden visual impairment and central scotoma was found to have a UAIM in her left eye. Three weeks after continuous worsening of her visual acuity and central scotoma, the patient was treated with intravitreal injections of aflibercept. The visual acuity increased and the macula lesion regressed, causing macula scarring after 2 injections. CONCLUSIONS: Intravitreal injections of aflibercept could be a therapy option in patients with UAIM without signs of spontaneous resolution of the clinical manifestations and visual improvement.
PURPOSE: To describe a case of unilateral acute idiopathic maculopathy (UAIM) response to intravitreal therapy with aflibercept (Eylea). METHODS: Retrospective case report. RESULTS: A 36-year-old woman with sudden visual impairment and central scotoma was found to have a UAIM in her left eye. Three weeks after continuous worsening of her visual acuity and central scotoma, the patient was treated with intravitreal injections of aflibercept. The visual acuity increased and the macula lesion regressed, causing macula scarring after 2 injections. CONCLUSIONS: Intravitreal injections of aflibercept could be a therapy option in patients with UAIM without signs of spontaneous resolution of the clinical manifestations and visual improvement.